CongressUpdate Haematologic diseases and potential future treatments: Award winners at the 2022 annual BSTH m... Read more
CongressUpdate Recent exposure to chemotherapy negatively impacts CAR-T cell treatment outcomes Read more
ASH 2021 Axicabtagene ciloleucel: potential new second-line standard of care for patients with relapsed... Read more
ASH 2021 Mosunetuzumab: effective and well-tolerated in the treatment of relapsed/refractory follicular... Read more
ASH 2021 Daratumumab plus VCd as a new standard of care for patients with newly diagnosed light-chain a... Read more
